부산대학교 도서관

A study published in the Journal of Internal Medicine evaluated the impact of switching from subcutaneous semaglutide to oral semaglutide in patients with type 2 diabetes (T2D) due to a shortage of the subcutaneous medication. The study included 43 patients who switched from once-weekly subcutaneous semaglutide to once-daily oral semaglutide. The results showed that there were no significant changes in weight or HbA1c levels after the switch, but treatment satisfaction decreased. The study suggests that oral semaglutide may be a useful alternative in the short term, but patients with previous use of subcutaneous semaglutide may prefer that treatment. [Extracted from the article]